Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

Patently absurd?

Article Abstract:

A Boston jury on May 4, 2006 ruled that the Eli Lilly osteoporosis drug Evista (raloxifene) and sepsis drug Xigris (activated protein C) infringed a patent held by the Massachusetts Institute of Technology (MIT), the Whitehead Institute and Harvard University, and exclusively licensed to Ariad Pharmaceuticals. The jury awarded Ariad $65.2 million in back royalties, as well a 2.3% royalty on future sales of Evista and Xigris through 2019.

Author: Garber, Ken, Arbor, Ann
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
Patents & copyrights, Pharmaceutical industry, Eli Lilly and Co., Intellectual property, LLY, Massachusetts Institute of Technology, Evista (Medication), Xigris (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


NIH licensing performance under par

Article Abstract:

A class of anticancer compounds called macrocyclic lactones, which were discovered by the National Institutes of Health (NIH) were licensed seven years after their discovery. The reasons for the delay could be attributed to heavy workload, high turnover amongst the licensing officers and lack of direct marketing at the NIH's Office of Technology Transfer (OTT).

Author: Garber, Ken, Arbor, Ann
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2004
Government regulation, Science & research, Management dynamics, Anticancer Drugs, Chemotherapeutic Drugs, Research, Management, Licensing, certification and accreditation, United States. National Institutes of Health, Antineoplastic agents, Company business management, Lactones, Antimitotic agents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Biotech industry faces new bottleneck

Article Abstract:

There is a serious shortage in recombinant protein therapeutic manufacturing capacity within the biotechnology industry. The industry must seek a way to produce all the proteins that are expected to win approval in the near future.

Author: Garber, Ken
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2001
Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences, Production management, Pharmaceutical Preparations, Drugs

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States
Similar abstracts:
  • Abstracts: Eating up performance. A sting in the tail
  • Abstracts: Estate planning. Banks and trust departments
  • Abstracts: Investment and financial planning. IRAs and retirement planning. Retirement planning
  • Abstracts: Financial and estate planning organizations. Investment planning. Financial planning
  • Abstracts: Spirit of adventure. A clutch of trusts venture forth. Pause to check the VCT small print
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.